Anticancer effects of paris saponins by apoptosis and PI3K/AKT pathway in gefitinib- Resistant non-small cell lung cancer

Medical Science Monitor

Volumn 22, Issue , 2016, Pages 1435-1441

  Zhu, Xinhai ^a   Jiang, Hao ^a,b   Li, Jinhui ^c   Xu, Ji ^d   Fei, Zhenghua ^b  

^a ZHEJIANG HOSPITAL   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Department of Surgery   (China)

Author keywords

Antineoplastic agents; Apoptosis; Carcinoma; Non small cell lung; Phosphatidylinositol 3 kinases

Indexed keywords

CASPASE 3; CASPASE 9; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SAPONIN; SAPONIN I; SAPONIN II; SAPONIN VI; SAPONON VII; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MTT ASSAY; NON SMALL CELL LUNG CANCER; PARIS (PLANT); PROTEIN EXPRESSION; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; IC50; LILIACEAE; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; LILIACEAE; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; SAPONINS; SIGNAL TRANSDUCTION;

EID: 84964838606     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.898558     Document Type: Article

References (38)

1. Lin L, Bivona TG: Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract, 2012; 2012: 817297
2. Ramalingam S, Sandler AB: Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist, 2006; 11: 655-65
3. Yan L, Gao W, Zhang Y, Wang Y: A new phenylpropanoid glycosides from Paris polychylia var. yunnanensis. Fitoterapia, 2008; 79: 306-7
4. Negi JS, Bisht VK, Bhandari AK et al: Paris polychylia: Chemical and biological prospectives. Anticancer Agents Med Chem, 2014; 14: 833-39
5. He H, Zheng L, Sun YP et al: Steroidal Saponins from Paris polychylia Suppress Adhesion, Migration and Invasion of Human Lung Cancer A549 Cells Via Down-Regulating MMP-2 and MMP-9. Asian Pac J Cancer Prev, 2014; 15: 10911-16
6. Cheng ZX, Liu BR, Qian XP et al: Proteomic analysis of anti-tumor effects by Rhizoma Paridis total saponin treatment in HepG2 cells. J Ethnopharmacol, 2008; 120: 129-37
7. Man S, Gao W, Zhang Y et al: Antitumor and antimetastatic activities of Rhizoma Paridis saponins. Steroids, 2009; 74: 1051-56
8. Sun J, Liu BR, Hu WJ et al: In vitro anticancer activity of aqueous extracts and ethanol extracts of fifteen traditional Chinese medicines on human digestive tumor cell lines. Phytother Res, 2007; 21: 1102-4
9. Lee MS, Yuet-Wa JC, Kong SK et al: Effects of polyphyllin D, a steroidal saponin in Paris polyphylla, in growth inhibition of human breast cancer cells and in xenograft. Cancer Biol Ther, 2005; 4: 1248-54
10. Chiang HC, Wang JJ, Wu RT: Immunomodulating effects of the hydrolysis products of formosanin C and betaecdysone from Paris formosana Hayata. Anticancer Res, 1992; 12: 1475-78
11. Wu RT, Chiang HC, Fu WC et al: Formosanin-C, an immunomodulator with antitumor activity. Int J Immunopharmacol, 1990; 12: 777-86
12. Lee JC, Su CL, Chen LL, Won SJ: Formosanin C-induced apoptosis requires activation of caspase-2 and change of mitochondrial membrane potential. Cancer Sci, 2009; 100: 503-13
13. Ma DD, Lu HX, Xu LS, Xiao W: Polyphyllin D exerts potent anti-tumour effects on Lewis cancer cells under hypoxic conditions. J Int Med Res, 2009; 37: 631-40
14. Shuli M, Wenyuan G, Yanjun Z et al: Paridis saponins inhibiting carcinoma growth and metastasis in vitro and in vivo. Arch Pharm Res, 2011; 34: 43-50
15. GuangLie C, WeiShi G, GaiLing H, JianPing C: Effect of Paris saponin on antitumor and immune function in U14 tumor-bearing mice. Afr J Tradit Complement Altern Med, 2013; 10: 503-7
16. Wen F, Yin H, Chen C et al: Chemical characteristics of saponins from Paris fargesii var. brevipetala and cytotoxic activity of its main ingredient, paris saponin H. Fitoterapia, 2012; 83: 627-35
17. Zhao Y, Kang LP, Liu YX et al: Steroidal saponins from the rhizome of Paris polychylia and their cytotoxic activities. Planta Med, 2009; 75: 356-63
18. Xiao X, Bai P, Bui Nguyen TM et al: The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. Mol Cancer Ther, 2009; 8: 1179-88
19. Xiao M, Dai X, He X et al: Paris saponin I induces G2/M cell cycle arrest and apoptosis in human gastric carcinoma SGC7901 cells. J Huazhong Univ Sci Technolog Med Sci, 2011; 31: 768-72
20. Jiang H, Su D, Ma SL: [The effect of Chonglou Saponin I on proliferation and apoptosis in lung adenocarcinoma cell line PC9. ] J Chin Oncol, 2012; 18: 166-69 [in Chinese]
21. Jiang H, Zhao PJ, Ma SL: [The effect of Paris saponin I on apoptosis associating with PI3K/Akt pathway in pancreatic carcinoma cell line PANC-1. ] J Chin Oncol, 2014; 20: 127-30 [in Chinese]
22. Jiang H, Zhao PJ, Feng JG et al: [Radiosensitivity of Paris saponin I on pancreatic carcinoma cell line PANC-1 in vitro. ] J Chin Oncol, 2014; 20: 483-87 [in Chinese]
23. Xiao X, Zou J, Bui-Nguyen TM et al: Paris saponin II of Rhizoma Paridis-a novel inducer of apoptosis in human ovarian cancer cells. Biosci Trends, 2012; 6: 201-11
24. Zhao P, Jiang H, Su D et al: Inhibition of cell proliferation by mild hyperthermia at 43°C with Paris saponin I in the lung adenocarcinoma cell line PC-9. Mol Med Rep, 2015; 11: 327-32
25. Jiang H, Zhao P, Feng J et al: Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line. Oncol Lett, 2014; 7: 2059-64
26. Jiang H, Zhao PJ, Su D et al: Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant nonsmall cell lung cancer in vitro and in vivo. Mol Med Rep, 2014; 9: 2265-72
27. Xiao X, Yang M, Xiao J et al: Paris saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration. Cancer Chemother Pharmacol, 2014; 73: 807-18
28. Li Y, Sun Y, Fan L et al: Paris saponin VII inhibits growth of colorectal cancer cells through Ras signaling pathway. Biochem Pharmacol, 2014; 88: 150-57
29. Fan L, Li Y, Sun Y et al: Paris saponin VII inhibits metastasis by modulating matrix metalloproteinases in colorectal cancer cells. Mol Med Rep, 2015; 11: 705-11
30. Zhao PJ, Song SC, Du LW et al: Paris Saponins enhance radiosensitivity in a gefitinib resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest. Mol Med Rep, 2016; 13: 2878-84
31. Zhang J, Yang Y, Lei L, Tian M: Rhizoma Paridis saponins induces cell cycle arrest and apoptosis in non-small cell lung carcinoma A549 cells. Med Sci Monit, 2015; 21: 2535-41
32. Ji Y, Ma SL, Zhang YP et al: Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells. Anticancer Drugs, 2009; 20: 832-37
33. Shih JY, Gow CH, Yang PC: EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med, 2005; 353: 207-8
34. Pao W, Miller VA, Politi KA et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2005; 2: e73
35. Yun CH, Mengwasser KE, Toms AV et al: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA, 2008; 105: 2070-75
36. Engelman JA, Zejnullahu K, Mitsudomi T et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007; 316: 1039-43
37. Bean J, Brennan C, Shih JY et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA, 2007; 104: 20932-37
38. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet, 2006; 7: 606-19